ArticleAnnals of clinical microbiology and antimicrobials2026
Species-dependent in polymyxin B heteroresistance: genomic insights into adaptive evolution in Enterobacteriaceae.
Article in Annals of clinical microbiology and antimicrobials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymyxin heteroresistance poses a growing challenge in antimicrobial resistance management, yet its epidemiological features and molecular basis across different bacterial species and environments remain poorly understood. This study aimed to systematically evaluate the prevalence and genomic mechanisms of heteroresistance in Escherichia coli and Klebsiella pneumoniae.
methodsA total of 416 isolates (272 E. coli and 144 K. pneumoniae) were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Polymyxin heteroresistance was characterized using population analysis profiling (PAP) with stability validation. All isolates underwent antimicrobial susceptibility testing (AST) and whole-genome sequencing (WGS) for genomic analysis. An in vitro induction model was used to track resistance evolution.
resultsHeteroresistance prevalence was significantly higher in animal-derived than human-derived E. coli (17.83% vs. 2.10%, p < 0.01). Animal-derived resistant subpopulations carried distinct mutations in the two-components systems (TCSs) phoPQ-pmrAB/D. Structural modeling indicated that a PmrB T156M substitution disrupts kinase domain integrity, potentially triggering heteroresistance. Community-associated K. pneumoniae showed lower heteroresistance rates than clinical strains (34.03% vs. 76.62%, p < 0.01), with divergent insertion sequence (IS) distributions in the mgrB gene (IS903B/ISKpn74 vs. ISKpn26/ISKpn14). When challenged with polymyxin pressure, K. pneumoniae exhibited a significantly faster progression to polymyxin resistance than E. coli.
conclusionsThis study emphasizes the persistent influence of historical agricultural polymyxin use on the development of heteroresistance among E. coli and K. pneumoniae with diverse sources. The complexity of heteroresistance requires more cautious antibiotic selection and tailored therapeutic strategies in clinical practice to combat antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.